Clinical trials: Neoplasms, Pharyngeal
Oropharynx Cancer
Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer
The aim of this research is to study the feasibility of neoadjuvant treatment before chemoradiation in "high risk" HPV-driven Oropharynx cancer
- Trial name
- IMMUNEBOOST (NCT03838263)
- Testing
- Nivolumab, Chemoradiation
- Where
- 11 sites in France
- Volunteers
- 62 people
- Sponsor
- UNICANCER
Nasopharyngeal Carcinoma
A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC
We define refractory nasopharyngeal carcinoma as the following: recurrence with radiation brain injury after radiotherapy, recurrence after the second or more courses of radiotherapy, standard treatment failure after recurrence…
- Trial name
- NCT02590133
- Testing
- Recombinant Human Endostatin Injection (Endostar), Fluorouracil (5-Fu), Nedaplatin
- Where
- China
- Volunteers
- 328 people
- Sponsor
- Yun-fei Xia
Nasopharyngeal Carcinoma
Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC
This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and safety of radical chemoradiotherapy plus oral capecitabine/teggio for 1 year in patients with N3.
- Trial name
- NCT04220528
- Testing
- Capecitabine/Tiggio
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Fujian Cancer Hospital
Cancer of Head and Neck
Swallowing Rehabilitation in Patients With Head and Neck Cancer Receiving Radiotherapy
Head and neck cancer has a negative impact in swallowing function and quality of life. Rehabilitation has proven its usefulness after radiation therapy (RT), but some studies suggest that interventions should be initiated prior…
- Trial name
- ReDyOR (NCT02900911)
- Testing
- Early rehabilitation, Late rehabilitation
- Where
- Spain
- Volunteers
- 52 people
- Sponsor
- Parc de Salut Mar
Nasopharyngeal Cancer
Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment
Multicentre , non-randomized, prospective clinical trial to assess efficacy of Nivolumab in treatment of nasopharyngeal cancer who progressed during or after platinum-based chemotherapy .
- Trial name
- NIVONASO-21 (NCT04875611)
- Testing
- Opdivo
- Where
- 4 sites in Poland
- Volunteers
- 32 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Nasopharyngeal Carcinoma
Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Several prospective randomized trials have demonstrated that concurrent chemoradiotherapy was superior to radiotherapy alone in the treatment of locoregionally advanced nasopharyngeal carcinoma (NPC).
- Trial name
- NCT02434614
- Testing
- Docetaxel,Cisplatin,Fluorouracil, Intensity-modulated radiation therapy (IMRT), Cisplatin
- Where
- 6 sites in China
- Volunteers
- 440 people
- Sponsor
- Wei Jiang
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
This phase II trial compares the effect of adding ipatasertib to pembrolizumab (standard immunotherapy) vs. pembrolizumab alone in treating patients with squamous cell cancer of the head and neck that has come back (recurrent) or…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT05172258
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 20 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
The study is an open-label phase I/II clinical trial. The study will enroll patients to receive neoadjuvant SBRT plus 1 or 2 doses of neoadjuvant pembrolizumab with concurrent ficerafusp alfa (4 doses) prior to definitive…
- Trial name
- NCT07552558
- Testing
- Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Washington University School of Medicine
Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma
Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma
Gemcitabine plus cisplatin (GC) is more effective than fluorouracil plus cisplatin in the treatment of recurrent or metastatic NPC (R/M-NPC). GC is the standard first-line chemotherapy regimen for this population.
- Trial name
- NCT03639467
- Testing
- Anlotinib plus gemcitabine/cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Medical Sciences
Nasopharyngeal Cancer
To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
The purpose of this study is to assess the efficacy of addition of zometa to anti-neoplastic treatment compared with anti-neoplastic treatment alone, as measured by the primary efficacy variable of SREs (Skeletal Related Events)…
- Trial name
- NCT00697619
- Testing
- Zometa (zoledronic acid)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Precancerous Condition
Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00978081
- Testing
- aminolevulinic acid hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Head and Neck Cancer
Lymphedema Treatment in Head and Neck Cancer Patients
The purpose of this research is to evaluate the result of treatment for neck lymphedema on throat pressure in patients who have received radiation therapy for head and neck cancer.
- Trial name
- NCT04276454
- Testing
- Flexitouch Plus system
- Where
- United States
- Sponsor
- Endeavor Health
Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma Diagnosis, Ultrasonography and Shear Wave Elastography
Evaluation of Swallowing Muscles Using Ultrasonography and Shear Wave Elastography in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma Diagnosis
The aim of this study is to evaluate the mylohyoid, geniohyoid and digastric muscles in patients with radiotherapy-induced dysphagia due to nasopharynx cancer using ultrasonography and shear wave elastography (SWE).
- Conditions
- Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma Diagnosis, Ultrasonography and Shear Wave Elastography, Evaluation of Swallowing Muscles
- Trial name
- NCT06934837
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Konya Beyhekim Training and Research Hospital
Locally Advanced Hypopharyngeal Cancer
Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen
To evaluate the efficacy and safety of adebrelimab combined with TP chemotherapy regimen as neoadjuvant therapy for locally advanced hypopharyngeal cancer
- Trial name
- NCT07137039
- Testing
- Adebrelimab+Albumin paclitaxel +Cisplatin
- Where
- China
- Volunteers
- 34 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Oropharynx Cancer
Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer
This study is designed for patients with a cancer of the oropharynx (tonsils or base of tongue) caused by the HPV virus. Traditional treatment involves surgery followed by six weeks of daily radiation therapy.
- Trial name
- NCT02908477
- Testing
- Adjuvant Radiation Therapy, Docetaxel, Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 228 people
- Sponsor
- Mayo Clinic
Nasopharynx Cancer, Head and Neck Cancer
U87 CAR-T in Patients With Advanced Head and Neck Tumors
This is a single-arm, open-label clinical study to evaluate the safety, tolerability, and efficacy of U87 injection solution in patients with advanced malignant head and neck tumors.
- Trial name
- NCT06614686
- Testing
- U87 autologous CAR T-cell
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Nasopharyngeal Neoplasms, Carcinoma, Squamous Cell
Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)
To test the therapeutic ratio of additional chemotheray on advanced nasopharyngeal carcinoma.
- Trial name
- NCT00563927
- Testing
- Conventional RT, Cisplatin, 5-fluorouracil
- Where
- 4 sites in China
- Volunteers
- 340 people
- Sponsor
- Hospital Authority, Hong Kong
Oropharyngeal Dysphagia
The Passy Muir Swallowing Self Training Device
This is a device evaluation study to determine the optimal stimulation characteristics for using vibrotactile stimulation as a sensory triggering device for self retraining in patients with chronic moderate to severe dysphagia.
- Trial name
- PMSST (NCT01765673)
- Testing
- Vibrotactile stimulation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- James Madison University
Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients.
- Conditions
- Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy
- Trial name
- NCT05941741
- Testing
- Intensity Modulated Radiation Therapy, Chemotherapy, Immune checkpoint inhibitor
- Where
- 3 sites in China
- Volunteers
- 380 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Squamous, Head and Neck Cancer
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
Background: Bortezomib acts on molecules in head and neck cancer cells that are important for the cells growth and survival. The drug may help make the cancer more sensitive to radiation and other chemotherapy drugs.
- Conditions
- Carcinoma, Squamous, Head and Neck Cancer, Oral Cancer, Laryngeal Cancer
- Trial name
- NCT01445405
- Testing
- Bortezomib (Velcade, PS-341), Cetuximab, Cisplatin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.